首页>
外文期刊>british journal of haematology
>Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma:in vitroevaluation
【24h】
Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma:in vitroevaluation
展开▼
机译：Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma:in vitroevaluation
Summary.An immunotoxin containing an anti‐CD30 monoclonal antibody (Ber‐H2) and saporin, a ribosome‐inactivating protein type 1, is described. It specifically inhibits protein synthesis by Hodgkin derived target cell lines with a very high efficiency (IC50ranging from 5 × 10–12M to 5.10∼14M, assaporin), while irrelevant immunotoxins do not. Present results suggest that this immunotoxin could be used forin vivotherapy as well as forex vivobone marrow purging in Hodgkin's disease and CD304+
展开▼
